European Disease Progression Monitor: Edition 7 | L.E.K. Consulting

European Disease Progression Monitor

Delivers evidence on the effects of the disease

The EU5 are at a critical juncture

Many of the conclusions reached in Edition 6 remain

Many of the conclusions reached in Edition 6 remain (cont.)

Unprecedented investment and collaboration

A 12-month development timeline for a COVID-19 vaccine

Once a vaccine becomes available

The potential demand for a COVID-19 vaccine

There has been a growing number

Increased testing is giving a more

People over 75 account for

Emerging data across the EU5

A reduction in the number of people

The EU5 is at a critical juncture

All EU5 nations are nearing

The manner of easing the lockdown

Confirmed cases have continued

Disclaimer

Sign-up here to receive Disease Progression Monitor updates.

Sign-up

Related Insights

Life Sciences & Pharma

Executive Insights

CAR-T: Unlocking Barriers to Adoption in Europe

June 23, 2020

L.E.K. Consulting reviews progress to date, outlines barriers to uptake and identifies potential catalysts for accelerating European CAR-T adoption.

Life Sciences & Pharma

Executive Insights

Five Essential Factors for a Successful Biopharma Product Launch

November 25, 2019

Rapid changes in the biopharma industry are making it increasingly difficult to launch new products successfully.

Organization & Performance

Published Articles

Working From Home after COVID-19: businesses need to allow flexibility, or they will lose…

May 4, 2020

As businesses consider the likely shape of recovery from lockdown, we have researched the impact of the current enforced experience of working from home…

MedTech

COVID-19

COVID-19 Impact on Asia-Pacific Hospitals: Edition 3

June 25, 2020

The top concerns for a number of hospitals (~30%) have shifted towards staff wellness, staff capacity and hospital finances due to revenue loss from…

Life Sciences & Pharma

Executive Insights

Managing Non-Core Assets: Innovative Funding Models for Biopharma Companies

May 15, 2020

We discuss some of the innovative funding models available and identify the key strategies for optimizing these types of deals.

Life Sciences & Pharma

Executive Insights

AI in Biopharma: Realizing the Promise

October 31, 2019

Artificial intelligence (AI) should enable biopharma companies to tackle the entrenched inefficiencies of the costly and time-consuming drug development…